Construction and Expression of A Bicistronic Vector Containing Human Bone Morphogenetic Protein 2 and Vascular Endothelial Growth Factor-165 Genes in Vitro
Tian Xiao-bin,Sun Li,Zhang Yu-kun,Gao Yong,Fu De-hao,Yang Shu-hua
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2009.04.0021
IF: 6.133
2009-01-01
Chinese Medical Journal
Abstract:It has been well documented that bone morphogenetic proteins (BMPs), a group of proteins belonging to the transforming growth factor-β (TGFβ) superfamily, can induce bone formation, both in vivo and in vitro. Bone morphogenetic protein-2 (BMP2) is a potent osteoinductive factor and is being evaluated as a bone growth inducer for orthopedic applications.1 Vascular endothelial growth factor (VEGF), the best-characterized angiogenic factor, plays an important role in bone growth via the endochondral ossification pathway. Here, we described the construction of a bicistronic vector encoding human BMP2 and VEGF165. This vector will aid in the investigation of angiogenic and osteogenic factor interaction in bone formation and bone healing. METHODS Construction of the pIRES-BMP2 expression vector The Xho1-BMP2-Mlu1 sequence from the vector pcDNA3.1-BMP22 was amplified by polymerase chain reaction (PCR). The product was digested with XhoI and MluI, separated by electrophoresis on a 1% agarose gel and isolated using an Agarose Gel DNA Extraction Kit (BioAsia, Shanghai, China). The purified product was then ligated with an XhoI and MluI digested pIRES vector (BD Biosciences, CA, USA) for 16 hours at 16°C in the presence of T4 ligase (TaKaRa, Japan). Competent E. coli DH5α were then transformed with the ligation mixture. Transformed bacteria were spread on LB agar plates and incubated overnight at 37°C. Single clones were then picked and grown in LB medium supplemented with ampicillin. Plasmid DNA from individual clones was isolated using a Vector Miniprep Kit (BioAsia) and analyzed by digestion with restriction endonucleases. Finally, the pIRES-BMP2 vector was sequenced. Construction of the pIRES-BMP2-VEGF165 expression vector An XbαI-VEGF165-NotI sequence, containing the human VEGF165 gene, was amplified by PCR from the vector pUC-CAGGS-VEGF165 and then subcloned into the XbaI and NotI sites of pIRES-BMP2 (The pUC-CAGGS-VEGF165 vector was a gift from Dr. LIU Xiao-bing of Tongji Medical College of Huazhong Science and Technology University, Wuhan, China). The engineered vector was propagated, isolated, analyzed and sequenced as described above. Cell culture and transfection Mouse marrow stromal cells (MSCs) were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, Germany) supplemented with 10% fetal bovine serum and 0.1 mg/ml penicillin + streptomycin at 37°C in an atmosphere of 5% CO2. The pIRES-BMP2-VEGF165 vector was transfected into MSCs by lipotransfection according to the manufacturer's protocol (Invitrogen, USA). After 48 hours, the transfected cells were analyzed directly for VEGF165 and BMP2 mRNA expression. Empty pIRES vector was used as a control. BMP2 and VEGF165 mRNA detection BMP2 and VEGF165 mRNA were detected in transfected cells by reverse transcription-PCR (RT-PCR). Total RNA was isolated from harvested cells using Trizol (BioAsia). First strand cDNA synthesis was performed using the First Strand cDNA Synthesis Kit (Fermentas, Lithuania). PCRs were performed using sense and antisense primers of BMP2 and VEGF165. Western blotting Total 107 transfected MSCs were washed twice in ice-cold phosphate buffered saline (PBS) and then lysed with 200 μl lysis buffer. After centrifugation (20 000 × g for 5 minutes), supernatants were analyzed by Western blotting. BMP2 and VEGF165 proteins were detected using anti-BMP2 antibody (Boster, Wuhan, China) at a 1:500 dilution and anti-VEGF165 antibody (Boster) at a 1:500 dilution, respectively. Proteins were detected using an ECL kit (Boster). Immunohistochemical analysis Transfected MSCs were cultured in conditioned media for 7 days. The cells were fixed in ice-cold methanol and incubated with anti-BMP2 antibody (Boster) at a 1:200 dilution or with anti-VEGF165 antibody (Boster) at a 1:500 dilution. Goat-anti-rabbit IgG antibody (Boster) was used as secondary antibody. RESULTS Cloning and validation of the bicistronic pIRES-BMP2-VEGF165 vector Restriction digestion mapping and DNA sequencing confirmed the correct engineering of BMP2 and VEGF165 cDNAs into the pIRES vector (Figure 1). The sequences of BMP-2 and VEGF165 within the pIRES-BMP2-VEGF165 vector were in agreement with the BMP2 (NM-001200) and VEGF165 (X 62568) sequences in the GenBank database.Figure 1.: Restriction enzyme digestion analysis of recombinant vector pIRES-BMP2-VEGF165. Lane 1: Marker. Lane 2: recombinant vector pIRES-BMP2-VEGF165. Lane 3: pIRES-BMP2-VEGF165 digested with XhoI/MluI. Lane 4: pIRES-BMP2-VEGF165 digested with XbaI/NotI.Expression of BMP2 and VEGF165 mRNAin vitro RT-PCR generated 1.2 kb and 592 bp products from pIRES-BMP2-VEGF165 transfected cells. Cells transfected with pIRES produced no RT-PCR products (Figure 2).Figure 2.: Co-expression of BMP2 and VEGF165 in mMSCs detected by RT-PCR. Lane 1: Marker. Lane 2: BMP2 amplification of mMSCs/pIRES-BMP2-VEGF165. Lane 3: BMP2 amplification of mMSCs/pIRES. Lane 4: VEGF165 amplification of mMSCs/pIRES-BMP2-VEGF165. Lane 5: VEGF165 amplification of mMSCs/pIRES.Expression of BMP2 and VEGF165 proteins BMP2 and VEGF165 proteins were detected by Western blotting analysis (Figures 3 and 4) and immunohistochemistry (Figure 5) using anti-BMP2 and anti-VEGF165 antibodies, respectively. MSCs transfected with pIRES-BMP2-VEGF165 were capable of BMP2 and VEGF165 protein expression.Figure 3.: Western blotting analysis of the BMP2 protein in transfected mMSCs. Lane 1: Cells transfected with bicistronic pIRES-BMP2-VEGF165 vector. Lane 2: Cells transfected with empty pIRES vector. Lane 3: Non-transfected cells.Figure 4.: Western blotting analysis of the VEGF165 protein in transfected mMSCs. Lane 1: Cells transfected with bicistronic pIRES-BMP2-VEGF165 vector. Lane 2: Cells transfected with empty pIRES vector. Lane 3: Non-transfected cells.Figure 5.: Immunohistochemistry analyses of the BMP2 (A) and VEGF165 (B) proteins expressed in transfected MSCs (Original magnification ×200).DISCUSSION BMPs were originally discovered in osteoinductive extracts of bone matrix. BMP2 is a potent osteoinductive factor, which has been shown to induce osteogenic differentiation of mesenchymal cells. BMP2 can stimulate differentiation of MSCs toward an osteoblastic lineage, thereby increasing the number of differentiated osteoblasts capable of forming bone.1 Recombinant human BMP2 (rhBMP2) is manufactured by a recombinant DNA biotechnology process and has been evaluated preclinically and clinically for use in the treatment of bone defects.3,4 Although BMP2 alone is sufficient to induce bone formation,5 bone regeneration is a multistep process involving many physiological and pathological phenomena. Angiogenesis is postulated to be a crucial step for new bone formation.6 VEGF, the best-characterized angiogenic factor, can enhance the formation of new vessels during endochondral ossification and bone healing.7,8 Blocking VEGF leads to a decrease in trabecular bone formation at the growth plate, secondary to suppression of blood vessel invasion and impairment of cartilage resorption.5 VEGF can up-regulate BMP2 mRNA and protein levels in endothelial cells.9,10 On the other hand, BMP2 can display angiogenic activity during bone formation by upregulating VEGF expression.11,12 These studies indicate that co-expression of BMP2 and VEGF may synergistically enhance bone formation and healing.13,14 The pIRES vector contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV). This sequence permits two genes of interest (in our case, BMP2 and VEGF165) to be separately translated from a single bicistronic mRNA. Additional advantages of bicistronic vectors compared with using two monocistronic vectors are lower costs of preparation and lower levels of endotoxins produced during vector preparation. In the present work we have constructed a bicistronic vector encoding BMP2 and VEGF165. This vector has the potential to be transfected in vivo into cells of restricted, localized sites to co-express the osteoinductive and angiogenic factors. The co-expression will enable the interaction between angiogenic and osteogenic factors in bone formation and bone healing to be investigated.